Ligand Pharmaceuticals Incorporated

NasdaqGM:LGND Stok Raporu

Piyasa değeri: US$5.1b

Ligand Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Ligand Pharmaceuticals şirketinin kazançları yıllık ortalama -2.5% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 9.4% oranında artan oldu. Gelirler yıllık ortalama 1.7% oranında azalan oldu. Ligand Pharmaceuticals şirketinin öz sermaye getirisi 15.4% olup, net marjı 55.9% dir.

Anahtar bilgiler

-2.50%

Kazanç büyüme oranı

-5.88%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi5.95%
Gelir büyüme oranı-1.67%
Özkaynak getirisi15.40%
Net Marj55.95%
Son Kazanç Güncellemesi31 Mar 2026

Yakın geçmiş performans güncellemeleri

Recent updates

Anlatı Güncellemesi • Jun 01

LGND: Expanded Royalty Portfolio And IP Duration Will Shape Future Upside

Analysts have raised their price target on Ligand Pharmaceuticals to $277.60 from $246.70, citing updated royalty assumptions around Filspari and revised expectations for revenue growth, margins and future P/E multiples. Analyst Commentary Recent research updates on Ligand Pharmaceuticals focus largely on changes to price targets, revisions to royalty assumptions around Filspari, and views on how the company can execute against its earnings plans.
Anlatı Güncellemesi • Apr 19

LGND: Royalty Portfolio And Partner Execution Will Shape Balanced Future Outlook

Ligand Pharmaceuticals' analyst price target has been nudged higher to about $247 from roughly $245, as analysts factor in slightly stronger modeled revenue growth, profit margins, and a modestly higher future P/E based on recent royalty pipeline updates and fresh coverage on the Street. Analyst Commentary Recent Street research on Ligand points to a cluster of higher price targets, fresh coverage and updated royalty assumptions, all of which feed into how analysts are thinking about valuation, execution risk and growth potential for the royalty portfolio.
Anlatı Güncellemesi • Apr 04

LGND: Royalty Pipeline And Phase 3 Progress Will Drive Future Upside

Analysts have nudged their price target for Ligand Pharmaceuticals to $245.10 from $244.50, reflecting updated views on higher potential revenue growth, a much wider projected profit margin, and a lower future P/E assumption in recent research. Analyst Commentary Recent research on Ligand Pharmaceuticals has been active, with several firms adjusting price targets and reiterating positive views on the company’s royalty driven model and pipeline exposure.
Anlatı Güncellemesi • Mar 21

LGND: Royalty Portfolio And Phase 3 Readout Will Support Future Upside

Analysts made a small adjustment to Ligand Pharmaceuticals' fair value estimate to $244.50 per share, reflecting updated modeling around its broad royalty portfolio and recent confidence in QTORIN related cash flow potential cited in recent price target and rating updates. Analyst Commentary Recent Street commentary around Ligand Pharmaceuticals centers on the breadth of its royalty portfolio, the progress of QTORIN, and how these factors could influence earnings power and valuation over time.
Anlatı Güncellemesi • Mar 06

LGND: Royalty Portfolio And 2026 Revenue Mix Will Support Future Upside

The analyst price target for Ligand Pharmaceuticals has been raised by $1.11. Analysts point to steady royalty revenue and increased expectations around QTORIN's potential following positive Phase 3 data as key supports for the updated valuation assumptions.
Anlatı Güncellemesi • Feb 19

LGND: Stable Fair Value And 2026 Revenue Mix Will Support Future Earnings

Analysts have modestly adjusted their price target on Ligand Pharmaceuticals, reflecting a slightly higher discount rate and a lower future P/E assumption, while keeping their fair value estimate effectively unchanged at $243.44. Analyst Commentary Recent Street research around Legence provides context for how analysts are thinking about valuation, execution, and growth drivers that may be relevant for investors following Ligand Pharmaceuticals, especially around themes such as data center demand, healthcare exposure, and capital allocation.
Anlatı Güncellemesi • Feb 05

LGND: Raised 2025 Guidance And Solid Quarter Will Support Future Earnings Power

Analysts have raised their price target on Ligand Pharmaceuticals to $234 from $185, reflecting their view that recent quarterly results and the 2025 guidance update support a higher valuation range for the shares. Analyst Commentary Recent research commentary around Ligand Pharmaceuticals centers on how the latest quarterly results and the 2025 guidance update feed into a higher valuation range, with US$234 now set as a new price target by one major firm.
Seeking Alpha • Jan 28

Ligand Pharmaceuticals: 2026 Guidance May Already Be Included In Current Valuation

Summary Ligand Pharmaceuticals (LGND) is a royalty investor in late-stage biopharma, with revenue and EPS growth driven by a robust portfolio. LGND expects royalty revenue to compound at a 23% CAGR through 2030, fueled by assets like Filspari, Ohtuvayre, and Zelsuvmi. Despite strong fundamentals and guidance, current valuation already prices in much of the anticipated 2026 growth; I rate LGND a Hold. Key risks include Filspari's regulatory uncertainty for FSGS and potential exclusivity loss on legacy royalty streams. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jan 22

LGND: Royalty Model And 2025 Guidance Raise Will Drive Future Earnings Power

Analysts have nudged their price targets on Ligand Pharmaceuticals higher into the low $230s, citing what they describe as strong recent quarterly results, raised 2025 guidance, and ongoing business development activity as key supports for the updated outlook. Analyst Commentary Recent research on Ligand Pharmaceuticals has focused on the implications of its latest quarter and the updated 2025 outlook, with several firms lifting their price targets into a tight range around the low US$230s.
Anlatı Güncellemesi • Jan 08

LGND: Royalty Model And 2025 Guidance Raise Will Support Earnings Power

Narrative Update Analysts have lifted their price target on Ligand Pharmaceuticals to the mid $230s, reflecting recent target increases to $234 and $231. They attribute these changes to what they describe as solid quarterly results, a 2025 guidance raise, and ongoing business development activity.
Anlatı Güncellemesi • Dec 24

LGND: Royalty Model Will Support Expanding Margins And Multi Year Earnings Power

Analysts have nudged their consolidated fair value estimate for Ligand Pharmaceuticals modestly higher to approximately $243 from $238 per share, citing stronger than previously modeled profitability, resilient margin expansion, and the continued validation of the company’s royalty driven model in recent research updates that raised price targets into the low $230s. Analyst Commentary Bullish analysts point to the latest price target increases into the low to mid $230s as evidence that Ligand is executing above prior expectations, with stronger earnings power and higher quality of revenue than previously modeled.
Anlatı Güncellemesi • Dec 09

LGND: Expanded Deal Pipeline Will Drive Multi Year Earnings Power

Analysts have nudged their average price target on Ligand Pharmaceuticals higher to the mid 230 dollar range. This reflects confidence in the company’s strong recent quarter, raised 2025 guidance, and a business model that continues to deliver robust earnings and margin performance.
Anlatı Güncellemesi • Nov 25

LGND: Upcoming Business Development Activity Will Drive Financial Momentum Into 2025

Ligand Pharmaceuticals' analyst price target increased from $206 to $238. Analysts cited better-than-expected quarterly results, raised future guidance, and continued strong business development activity as key drivers for the upward revision.
Anlatı Güncellemesi • Nov 07

LGND: Capital Flexibility And Business Model Will Shape Mid-Term Performance Outlook

Ligand Pharmaceuticals’ analyst price target has increased from $183.13 to $206.25. Analysts cite robust Q3 results and an ongoing strong business development model as key drivers for the upward revision.
Anlatı Güncellemesi • Sep 13

Expanding Royalty Portfolio Will Strengthen Global Healthcare Reach

Ligand Pharmaceuticals’ consensus price target was raised from $178.12 to $183.12, reflecting analysts’ confidence in its strengthened capital position following a successful $460M convertible debt offering, robust revenue and earnings guidance, and a track record of prudent capital allocation and royalty portfolio wins. Analyst Commentary Market enthusiasm following Ligand's successful $460M convertible debt offering, which provided $385M in net capital and included a $45M bond hedge mitigating dilution up to $294/share, as well as a $15M share repurchase.
Anlatı Güncellemesi • Aug 29

Expanding Royalty Portfolio Will Strengthen Global Healthcare Reach

Ligand Pharmaceuticals' consensus price target was raised to $173.38, reflecting better-than-expected Q2 results, higher FY25 revenue and EPS guidance, growing investor confidence in its royalty portfolio, and successful strategic investments. Analyst Commentary Better-than-expected Q2 results and an increase in FY25 guidance, indicating improved near-term financial performance.
Anlatı Güncellemesi • Aug 08

Expanding Royalty Portfolio Will Strengthen Global Healthcare Reach

Ligand Pharmaceuticals’ consensus price target has increased to $154.75, primarily driven by a notable surge in net profit margin and a sharp reduction in future P/E, indicating improved profitability and valuation. What's in the News Ligand Pharmaceuticals raised 2025 revenue guidance to $200–225 million from $180–200 million.
Seeking Alpha • Apr 20

Revisiting Ligand Pharmaceuticals, Ready To Accumulate If Shares Dip Below $100

Summary Ligand Pharmaceuticals' diversified royalty platform offers strong biotech exposure with reduced risk, supported by robust royalty revenue growth and a solid cash position. Despite a 28% royalty revenue growth in 2024, Ligand's stock is fairly priced at around $97 based on our calculations. Key assets like Captisol, Qarziba, Ohtuvayre, and Filspari drive revenue, but clinical setbacks or commercial execution risks could impact future growth. Downgrade from Buy to Hold due to current valuation; consider accumulating shares if the stock drops below $100. Read the full article on Seeking Alpha
Seeking Alpha • Feb 03

Looking Back On Ligand Pharmaceuticals

Summary Today, I am circling back to Ligand Pharmaceuticals for the first time since late 2023. The stock has had a nice run in recent months and management has a solid game plan to grow revenues at north of 20% annually in the years ahead. Analysts are universally optimistic, with multiple Buy ratings and price targets ranging from $135 to $160 a share. An updated analysis around Ligand Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Nov 24

Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies

Summary I continue to rate Ligand Pharmaceuticals stock as a "Buy" citing strong liquidity and a clean balance sheet. Its Q3 2024 earnings report beat on the top and bottom lines raising prior guidance, reinforcing my confidence in the company's performance. This analysis references Q3 2024 financial results press release, earnings conference call, presentation, 10-Q, and the latest 10-K. Ligand's solid financial position and consistent performance make it a positive investment choice. Read the full article on Seeking Alpha
User avatar
Yeni Anlatı • Sep 12

Expanding Royalty Portfolio And Calculated Acquisitions Set To Skyrocket Revenue And Margins

Significant investment in new opportunities and acquisitions, including Apeiron Biologics, aimed at increasing royalty revenue and diversifying the revenue base.
Seeking Alpha • Jul 29

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Summary Ligand Pharmaceuticals has seen over a 50% increase in share value since its Q1 earnings report. Recent positive developments include new deals, regulatory successes, and raising 2024 guidance. A new deal of close to $200 million with Agenus and $100 million acquisition of APEIRON contribute to the positive outlook. Read the full article on Seeking Alpha
Seeking Alpha • Apr 30

Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio

Summary Royalty Aggregators like Royalty Pharma, Ligand, and XOMA are gaining popularity in the biotech industry. These companies buy up royalty rights to pharmaceutical products, providing upfront cash to biotech companies. This allows biotech companies to access immediate funds for research and development, while the aggregators earn a return on their investment. Read the full article on Seeking Alpha

Gelir ve Gider Dağılımı

Ligand Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGM:LGND Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
31 Mar 26274154940
31 Dec 25268124920
30 Sep 2525149930
30 Jun 25188-76890
31 Mar 25181-133870
31 Dec 24167-4790
30 Sep 2415245690
30 Jun 2413342590
31 Mar 2411896530
31 Dec 2313154530
30 Sep 2315421680
30 Jun 2318041680
31 Mar 2320451690
31 Dec 22196-5700
30 Sep 2218323460
30 Jun 2218827440
31 Mar 2222345460
31 Dec 2124276470
30 Sep 2127568490
30 Jun 2125248510
31 Mar 2120839470
31 Dec 201647390
30 Sep 20143-16450
30 Jun 20126-25390
31 Mar 20110-61400
31 Dec 19120629420
30 Sep 19153594430
30 Jun 19174677430
31 Mar 19239764410
31 Dec 18251143380
30 Sep 18242179340
30 Jun 18230120320
31 Mar 1816853290
31 Dec 1714113290
30 Sep 1712916280
30 Jun 171179270
31 Mar 17109-3280
31 Dec 16109-2280
30 Sep 16927270
30 Jun 1688205250
31 Mar 1687235250
31 Dec 1572230250
30 Sep 1574231240
30 Jun 157133250

Kaliteli Kazançlar: LGND yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: LGND geçmişte karlı hale geldi.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: LGND şirketinin kazançları son 5 yılda yılda 2.5% oranında azaldı.

Büyüme Hızlandırma: LGND son bir yılda karlı hale geldi, bu da kazanç büyüme oranının 5 yıllık ortalamayla karşılaştırılmasını zorlaştırıyor.

Kazançlar vs. Sektör: LGND son bir yılda karlı hale geldi ve bu durum, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( -4.8% ) karşılaştırılmasını zorlaştırıyor.

Özkaynak Getirisi

Yüksek ROE: LGND 'nin Özsermaye Getirisi ( 15.4% ) düşük olarak değerlendiriliyor.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/06/14 15:19
Gün Sonu Hisse Fiyatı2026/06/12 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Ligand Pharmaceuticals Incorporated 20 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Jasper HellwegArgus Research Company
Robert WassermanBenchmark Company
Jason ZemanskyBofA Global Research